Xencor (XNCR) Retained Earnings (2013 - 2026)
Xencor (XNCR) posted quarterly Retained Earnings of $27000.0 for Q1 2026, down 100.0% year-over-year from $1.4 billion in Q1 2025, and up 100.0% quarter-over-quarter from -$796.0 million in Q4 2025.
Analysis
Xencor (XNCR) Retained Earnings (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Retained Earnings for 14 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 100.0% year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $27000.0 (down 100.0% YoY), while the FY2025 annual figure was -$796.0 million, down 157.61% from the prior year.
- Retained Earnings climbed to $27000.0 in Q1 2026 per XNCR's latest filing, from -$796.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.4 billion in Q1 2025 and bottomed at -$796.0 million in Q4 2025.
- Historically, Retained Earnings has averaged $149.6 million across 5 years, with a median of -$652000.0 in 2024.
- On a YoY basis, Retained Earnings climbed as much as 903516.23% in 2025 and fell as far as 120034.82% in 2025.
- Xencor's Retained Earnings stood at -$338.3 million in 2022, then soared by 100.38% to $1.3 million in 2023, then surged by 106918.36% to $1.4 billion in 2024, then plunged by 157.61% to -$796.0 million in 2025, then surged by 100.0% to $27000.0 in 2026.
- Business Quant data shows XNCR's Retained Earnings at $27000.0 in Q1 2026, -$796.0 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 1.45 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.45 Bn |
| Mar 31, 2026 | 1.44 Bn |
| Dec 31, 2025 | 1.43 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.40 Bn |
| Mar 31, 2025 | 1.39 Bn |
| Dec 31, 2024 | 1.38 Bn |
| Sep 30, 2024 | 1.36 Bn |
| Jun 30, 2024 | 1.16 Bn |
| Mar 31, 2024 | 1.14 Bn |
| Dec 31, 2023 | 1.13 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.10 Bn |
| Mar 31, 2023 | 1.09 Bn |
| Dec 31, 2022 | 1.07 Bn |
| Sep 30, 2022 | 1.06 Bn |
| Jun 30, 2022 | 1.04 Bn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 1.02 Bn |
| Sep 30, 2021 | 974.51 Mn |